Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd ...
April 29 2020 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines, today
announced that the company will present preclinical data from its
oncology pipeline of Red Cell Therapeutics™ (RCTs) at the American
Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting. The
meeting is being held virtually from May 12 – 15, 2020.
“At Rubius Therapeutics, we are engineering Red Cell
Therapeutics to replicate how the immune system naturally fights
cancer. At the ASGCT Annual Meeting, we plan to present preclinical
data from our lead artificial antigen-presenting cell (aAPC)
program, RTX-321, for the treatment of HPV 16-positive tumors,
demonstrating that we can activate and expand antigen-specific T
cells for tumor-specific immunotherapy in vitro. Importantly, we
will show that we can expand the different cell populations that
are critical for delivering and maintaining long-term, anti-tumor
responses. We plan to file an Investigational New Drug application
for RTX-321 by the end of 2020,” said Laurence Turka, M.D., chief
scientific officer of Rubius Therapeutics. “Additionally, we plan
to present data showing that our aAPC platform can expand both
naïve and exhausted CD4+ T cells in vitro. This finding is
significant because both of these cell types may be present in
patients with HPV 16-positive cancers, suggesting that we may be
able to harness the full complement of tumor-specific CD4+ T cells
to achieve durable responses in patients.”
The abstracts can be accessed via the ASGCT website meeting
planner. All posters will be made available at the beginning of the
virtual meeting on Tuesday, May 12, 2020, at 6:00 a.m. ET and
during the poster presentation sessions:
Abstract Title: An Engineered Allogeneic
Artificial Antigen Presenting Red Cell Therapeutic, RTX-321, for
HPV16+ Associated Cancers Promotes Antigen-Specific T Cell
Activation & ExpansionSession Date/Time:
Tuesday, May 12, 2020 5:30 PM - 6:30 PM ETSession
Title: Cancer - Immunotherapy, Cancer
VaccinesAbstract Number: 321
Abstract Title: Engineered Red-Cell
Therapeutics (RCT) as Artificial Antigen Presenting Cells Promote
In Vitro Expansion of Both Naïve and Exhausted CD4+ T
CellsSession Date/Time: Thursday, May 14, 2020
5:30 PM - 6:30 PM ETSession Title: Cancer -
Immunotherapy, Cancer VaccinesAbstract Number:
1149
About Rubius TherapeuticsRubius Therapeutics is
a clinical-stage biopharmaceutical company developing a new class
of medicines called Red Cell Therapeutics™. The Company’s
proprietary RED PLATFORM® was designed to genetically engineer and
culture Red Cell Therapeutics™ that are selective, potent and
off-the-shelf allogeneic cellular therapies for the potential
treatment of several diseases across multiple therapeutic areas.
Rubius’ initial focus is to advance RCT™ product candidates for the
treatment of cancer and autoimmune diseases by leveraging two
distinct therapeutic modalities — potent cell-cell interaction and
tolerance induction. For more information, visit www.rubiustx.com,
follow us on Twitter or LinkedIn or like us on Facebook.
Forward Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, statements regarding the, our
expectations regarding the therapeutic potential of our Red Cell
Therapeutics, including RTX-321 for the treatment of HPV
16-positive tumors, the timelines for us to file an IND for
RTX-321, and our strategy, business plans and focus, including our
plans to present preclinical data at the ASGCT 23rd Annual Meeting.
The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
development of our Red Cell Therapeutic product candidates and
their therapeutic potential and other risks identified in our SEC
filings, including our Annual Report on Form 10-K for the year
ended December 31, 2019, and subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. We
disclaim any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
Contact:Lori Melançon, Vice President,
Corporate Communications and Investor Relations+1 (617)
949-5296lori.melancon@rubiustx.com
Media Contact: Dan Budwick, 1AB+1 (973)
271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024